These firms are very niche but growing steadily and have Ebos CEO John Cullity's attention

These firms are very niche but growing steadily and have Ebos CEO John Cullity's attention
Ebos chief executive John Cullity says shareholders can expect more buying in Southeast Asia. (Image: Ebos)
Rebecca Stevenson
Listed healthcare and pet company Ebos says it sees investment potential in regenerative medicine firm Origin Biologics. Dual-listed Ebos reported its full-year result on Wednesday, with sales revenue exceeding A$13.2 billion (NZ$14.4b) for the first time. Ebos is known for its canny acquisitions and chief executive John Cullity said the company would continue its foray into Southeast Asia and medical devices, but there were also opportunities in the US. Ebos completed a major acquisition in 2022 when it purchased Lifehealthcare,...

More Markets

Seeka’s revenue climbs 34% on increased kiwifruit volumes
Primary Sector

Seeka’s revenue climbs 34% on increased kiwifruit volumes

Zespri announced its forecasts for the season this week.

ComCom increases Chorus spending allowance to $1.7b
Markets

ComCom increases Chorus spending allowance to $1.7b

$128.4m more was approved for the next regulatory period over the draft decision.

Ben Moore 10:25am
Auckland Airport's underlying profit up 87%
Markets

Auckland Airport's underlying profit up 87%

Company will pay a final dividend of 6.5c a share on October 4. 

SkyCity's profits drop in year of 'considerable upheaval'
Markets

SkyCity's profits drop in year of 'considerable upheaval'

SkyCity's turnaround year turned out to be anything but.